Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Globe Newswire9-09-2024, 22:45
Japan’s Kajima Corporation Makes Direct Investment in Eavor Technologies Inc. 20-02-2024, 22:16
